N/A N=113,035 Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
Stroke
Primary: All-cause Mortality During Hospitalization of Acute Ischemic Stroke (AIS) Patients — 2.6; 0.8 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12,551 1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
Stroke
Primary: All-cause Mortality at 1 Year (Percentage of Patients With Modified Rankin Scale (mRS) Score =6) — 11.1; 12.2 Percentage of Participants — p=0.183
N/A N=1,560 Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
Stroke
Primary: Percentage of Patients With Favourable Outcome (Modified Rankin Scale (mRS) 0-1) at 1 Year — 27.7; 23.8 Percentage of Participants — p=<0.001
Phase 2 N=88 A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects
Acute Ischemic Stroke
Primary: The Proportion of Subjects With Adverse Events (AEs), Judged to be Probably or Definitely Related to the Investigational Product (IP), Within 90 Days After the First IP…
N/A N=80 Deep Learning Enabled Endovascular Stroke Therapy Screening in Community Hospitals
Acute Ischemic Stroke (AIS)
Primary: Time From Emergency Room Arrival to Initiation of Endovascular Stroke Therapy ("Door-to-groin" Time) — 100; 88 minutes
Phase 3 N=458 Tenecteplase in Stroke Patients Between 4.5 and 24 Hours
THROMBOLYSIS
Primary: Ordinal Modified Rankin Scale (mRS) Score at Day 90 — 35; 31; 38; 30 Count of participants
Phase 1 N=24 A Phase Ib/II in Patients With Acute Ischemic Stroke
Ischemic Stroke
Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities
N/A N=42,188 Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
Stroke
Primary: Percentage of Patients Who Received Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treatment Within 3 Hours of Symptom Onset Among 2 Hours Intravenous…
Phase 1 N=57 The Capillary Index Score Trial
Acute Stroke · Brain Ischemia · Ischemic Stroke
Primary: Modified Rankin Score (mRS) Between Favorable CIS Group Versus Poor CIS Group. — 22; 1; 23; 10 Participants
Phase 2 N=106 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
Acute Ischemic Stroke · Thrombotic Disease
Primary: Summary of Treatment-Emergent Adverse Event Reported by >10% of Participants Following Ascending Doses of DS-1040b and a Placebo in Participants With Acute Ischemic…
N/A N=984 Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry
Ischemic Stroke
Primary: Number of Participants Assessed for Revascularization With mTICI Grades 2b-3 — 724 Participants
Phase 2 N=6 A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)
Arterial Ischemic Stroke
Primary: Changes in Volume of Infarct — 9.97; 4.06 mL — p=0.0313
Phase 4 N=80 Human Urinary Kallidinogenase Improve Short Term Motor Functional Outcome of Acute Ischemia Stroke Patients
Stroke, Acute
Primary: Myelin Basic Protein (MBP) Comparison Between the Two Groups Before and After Treatment — 0.42; 0.64; 0.41; 0.71 pg/ml
N/A N=16 American Heart Association- Stroke/Hypoxia Study
Stroke
Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants
N/A N=1,196 Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Stroke Care
Stroke · Stroke, Ischemic · Stroke, Acute
Primary: Stroke Impact Scale (SIS) at 12-months Post-discharge — 80.42; 83.85 Score
Phase 3 N=336 Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS
Ischemic Stroke
Primary: Good Functional Recovery — 84; 68 patients — p=<0.01
Phase 4 N=457 Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
Cerebral Infarction · Atherosclerosis
Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants
Phase 2 N=18 Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Ischemic Stroke
Primary: Symptomatic Intracerebral Hemorrhage (ICH) — 1; 1 participants
Phase 2 N=40 Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study
Ischemic Stroke
Primary: Technical Device Success by as Assessed by the Percentage of Participants Which Established at Least TIMI 2 Flow Upon Deployment of the System Across the Occlusion and…
N/A N=196 Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial
Acute Ischemic Stroke
Primary: 90-day Global Disability Assessed Via the Blinded Evaluation of Modified Rankin Score (mRS). — 17; 8; 25; 10 Participants
N/A N=400 Investigation of Clot in Ischemic Stroke and Hematoma Evacuation
Ischemic Stroke · Intracranial Hematoma
Primary: Clot Specimen Histology — 373; 12 Count of specimen
Phase 2 N=126 Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke
Ischemic Stroke · Stroke · Brain Infarction
Primary: Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours of Treatment Onset — 3; 2; 22; 99 participants — p=0.053
Phase 2 N=20 Safety of Intravenous Thrombolytics in Stroke on Awakening
Stroke
Primary: Number of Participants With Symptomatic Intracerebral Hemorrhage Within 36 Hours of Treatment — 0 participants
Phase 2 N=277 Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Acute Ischemic Stroke
Primary: Percentage of Participants With Composite Global Measure of Functional Disability Excellent Outcome at Day 90 — 54.1; 41.5; 39.9 percentage of participants — p=0.086
Phase 4 N=401 Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
Cerebral Infarction
Primary: the Rate of Patients With a Modified Rankin Scale Score of 0-1 — 109; 98; 46; 39 participants
Phase 2 N=31 NeuroCognition After Carotid Recanalization
Cognition Disorder · Stroke · Occlusion Carotid
Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale
Phase 3 N=1,274 A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
Stroke, Acute
Primary: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) — 309; 338 Participants
N/A N=352 SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke
Acute Ischemic Stroke
Primary: Degree of Disability/Dependence as Measured by the Modified Rankin Scale (mRS) Score — 4; 5 scores on a scale
Phase 2 N=161 Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
Acute Ischemic Stroke
Primary: Change in Infarct Volume From Baseline (Diffusion-Weighted Imaging [DWI]) to Day 5 (Fluid-Attenuated Inversion Recovery [FLAIR]) — 2.17; 2.37 mL — p=0.779
Phase 2 N=88 A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Acute Stroke
Primary: Number of Subjects With Symptomatic Intracerebral Hemorrhage — 1; 1 Participants